Caribou Biosciences announced it is discontinuing its CAR-T cell therapy programs, evaluating strategic alternatives, and implementing significant job cuts, leading to a 38% drop in shares to $0.70 after hours.

Observed price moves

• CRBU-15.01%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.